TY - JOUR
T1 - Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease
AU - Sinclair, Eleanor
AU - Trivedi, Drupad K.
AU - Sarkar, Depanjan
AU - Walton-Doyle, Caitlin
AU - Milne, Joy
AU - Kunath, Tilo
AU - Rijs, Anouk M.
AU - de Bie, Rob M.A.
AU - Goodacre, Royston
AU - Silverdale, Monty
AU - Barran, Perdita
N1 - Funding Information: We thank Michael J Fox Foundation (grant ref:12921) and Parkinson’s UK (grant ref: K-1504) for funding this study. This work was supported by an EPSRC DTA grant to the School of Chemistry, which has funded the PhD project of E.S., a BBSRC DTP grant which has funded the PhD project of C.W.D. (BB/R505869/1) and the BBSRC (award BB/L015048/1) for instrumentation used in this work. We also thank our recruitment centres (See supporting information for lead personnel) for their enthusiasm and rigor during the recruitment process. We are very grateful to all the participants who took part in this study as well as PIs and nurses across all the recruiting centres. We also thank Richard Weller for feedback and discussions on sebum and dermatology. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.
AB - Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.
UR - http://www.scopus.com/inward/record.url?scp=85102439061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102439061&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-021-21669-4
DO - https://doi.org/10.1038/s41467-021-21669-4
M3 - Article
C2 - 33707447
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1592
ER -
